west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "慢性肾衰" 4 results
  • 重组人肝再生增强因子对慢性肾衰竭大鼠的保护作用

    【摘要】目的 探讨重组人肝再生增强因子(rocombinant human augmenter of liver regeneration,rhALR)对5/6肾切除所致慢性肾衰竭大鼠肾功能的保护作用。 方法 将雄性SD大鼠分为假手术组、对照组及rhALR组,以rhALR对5/6肾切除所致慢性肾衰竭大鼠进行治疗,比较各组大鼠血清尿素氮(BUN)、肌酐(Scr)及肾脏病理改变各项指标。结果 5/6肾切除后,大鼠血中Scr及BUN升高,病理学检查见肾间质纤维化,慢性肾衰竭大鼠模型制备成功。给予rhALR能降低慢性肾衰竭大鼠血中Scr及BUN水平,减少肾间质纤维化面积。结论 rhALR可有效降低5/6肾切除所致慢性肾衰竭大鼠的Scr及BUN水平,改善肾脏病理改变,延缓慢性肾衰竭进展,保护残肾功能。

    Release date:2016-09-08 09:31 Export PDF Favorites Scan
  • The Experience of Treatment of the Chronic Renal Failure Combination with Acute Left Heart Failure

    目的:分析探讨终末期慢性肾衰竭(CRF)并急性左心衰的发病机制及救治措施。方法:对36例各种原因所致的终末期CRF患者并急性左心衰采用药物控制血压,降低外周血管阻力,减轻心脏后负荷及采用血液透析等方法,减轻心脏前负荷,控制心衰。结果:36例患者2286次来院救治并发急性左心衰1144次,抢救成功1138次,成功率99.5%。结论:终末期CRF并急性左心衰据发病机理不同,给予不同处理,关键是尽快控制血压,脱水,降低外周血管阻力和控制血容量,降低心输出量。

    Release date:2016-09-08 10:00 Export PDF Favorites Scan
  • 超声评价慢性肾衰竭心脏功能的研究进展

    慢性肾衰竭的发病率和死亡率很高,严重威胁着人们的健康及生命。血液透析能够延缓慢性肾衰竭的进程,但心血管疾病仍是慢性肾衰竭维持性血液透析患者的主要并发症,也是慢性肾衰竭患者的首要死亡原因。慢性肾衰竭心脏结构和功能与预后密切相关,因此,准确评价慢性肾衰竭心脏的结构与功能,对临床诊断及其治疗具有重要意义。该文从超声医学角度,介绍了目前评估慢性肾衰竭心脏结构及功能的方法。

    Release date:2017-12-25 06:02 Export PDF Favorites Scan
  • Therapeutic effect and prognostic factors of vitrectomy for proliferative diabetic retinopathy in patients with chronic renal failure

    Objective To investigate the efficacy and prognostic factors of pars plana vitrectomy (PPV) in the treatment of proliferative diabetic retinopathy (PDR) with chronic renal failure (CRF). MethodsA retrospective study. From January 2016 to June 2021, a total of 82 eyes of 58 patients diagnosed with PDR combined with CRF and treated with PPV in Department of Ophthalmology, The Second Hospital of Hebei Medical University were included in the study. There were 32 cases in males and 26 cases in females. The mean age was (48.45±10.41) years. The course of renal failure was (4.15±3.23) years, and the course of diabetes was (14.45±6.71) years. All patients undergo best-corrected visual acuity (BCVA). The BCVA examination was performed using the international standard Snellen visual acuity chart, which was converted to logarithm of the minimum angle of resolution (logMAR) visual acuity for recording. The mean number of logMAR BCVA was 2.04±0.82 (0.7-2.8). The duration of vitreous hemorrhage averaged (2.65±1.55) months. There were 38 eyes (46.3%, 38/82) with traction retinal detachment; 32 eyes had a history of panretinal photocoagulation (PRP) treatment (39.0%, 32/82). All eyes were treated with 25G PPV. Patients with traction retinal detachment were treated with intravitreal injection of anti-vascular endothelial growth factor (VEGF) 3 days before surgery. Opacification of the lens affected the operation operator combined with phacoemulsification. Biochemical indexes such as hemoglobin, glycosylated hemoglobin, albumin, creatinine, uric acid, and alternative treatment (non-dialysis/hemodialysis/peritoneal dialysis) were collected. Postoperative follow-up time was ≥6 months. χ2 test or Fisher's exact test were used for comparison between groups. A logistic regression model was used for multivariate analysis, and Spearman correlation analysis was used to evaluate the correlations between variables. ResultsAt 6 months after surgery, the mean logMAR BCVA was 1.16±0.57. Compared with logMAR BCVA before surgery, the difference was statistically significant (t=-0.837, P<0.001); 44 eyes had BCVA ≥0.1 and 38 eyes had BCVA <0.1. Postoperative vitreous hemorrhage (PVH) was observed in 17 eyes after surgery (20.7%, 17/82). PVH occurred in 15 (46.9%, 15/32), 1 (2.3%, 1/44), and 1 (16.7%, 1/6) eyes in patients without dialysis, hemodialysis and peritoneal dialysis, respectively. There was significant difference between those without dialysis and those on hemodialysis (χ2=26.506, P<0.05). There was no significant difference between peritoneal dialysis patients and those without dialysis and hemodialysis patients (χ2=2.694, 2.849; P>0.05). PVH occurred in 3 (10.0%, 3/30) and 14 (27.0%, 14/52) eyes of vitreous cavity filled with silicone oil and perfusion fluid, respectively. The difference was statistically significant (χ2=3.315, P<0.05); 1 (33.3%, 1/3) and 10 (71.4%, 10/14) eyes were treated with PPV again, respectively, and the difference was statistically significant (P<0.05). Neovascular glaucoma (NVG) occurred in 12 eyes (14.6%, 12/82). Logistic regression analysis showed that age [odds ratio (OR) =0.911, P<0.05], diabetic retinopathy (DR) stage (OR=7.229, P<0.05), renal failure duration (OR=0.850, P<0.05), operation time (OR=1.135, P<0.05) was an independent risk factor for poor vision prognosis. Diabetes duration (OR=1.158, P<0.05), renal failure duration (OR=1.172, P<0.05) and alternative therapy were independent factors affecting the occurrence of PVH. Diabetes duration (OR=1.138, P<0.05) and renal failure duration (OR=1.157, P<0.05) were independent risk factors for postoperative NVG. Spearman correlation analysis showed that PVH was strongly correlated with post-operative NVG (r=0.469, P<0.01). There was no significant correlation between blood glucose, hemoglobin, creatinine and blood urea nitrogen and prognosis of postoperative vision, PVH and NVG occurrence (P>0.05). ConclusionsIn PDR patients with CRF, DR Stage, age, renal failure course and operation duration are correlated with vision prognosis. Compared with those who do not receive alternative therapy, hemodialysis treatment can reduce the occurrence of PVH and NVG after surgery.

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content